The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

New Functional Data on Our Spike Monoclonal Antibodies

Data on our anti-SARS-CoV-2 Spike S1 monoclonal antibodies shows that they are suitable for the investigation of antibody, antigen and receptor binding interactions between different Spike variants including the E484K receptor-binding domain mutation. The data shown here includes:

•  Differential binding of our anti-Spike S1 antibodies against our E484K Spike S1 protein

•  Differential inhibition of binding between our Wuhan-Hu-1 Spike RBD and ACE2 by our anti-Spike S1 antibodies

•  Neutralisation of  Wuhan-Hu-1 Spike-pseudotyped lentivirus by our anti-Spike S1 antibodies

Reagents

For product-specific information on our antibodies, E484K Spike S1 and ACE2 receptor proteins, please click on the buttons below:

Functional Binding Data

The following ELISA and pseudotype neutralisation data are shown for these products below:

ELISA: Anti-RBD Monoclonal Antibodies vs. Spike S1 (E484K Mutant)

ELISA: Anti-RBD Monoclonal Antibodies vs. Spike S1 (E484K Mutant)

Competitive ELISA: ACE2 vs. Anti-RBD Monoclonal Antibodies Against RBD-Coated Plates

Competitive ELISA: ACE2 vs. Anti-RBD Monoclonal Antibodies Against RBD-Coated Plates

Competitive ELISA: ACE2 vs. Anti-RBD Monoclonal Antibodies Against RBD-Coated Plates

Neutralisation Assay: Lentiviral-Spike Neutralisation by Anti-RBD Monoclonal Antibodies

Pseudotype micro-neutralisation assays were carried out by Dr Diego Cantoni, Dr Martin Mayora-Neto and Dr Nigel Temperton at the Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent.

Got any questions? Please get in touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

5 + 10 =